Announcements Trials
Browse Landscape

Phase

Phase 1 1

Status

Not yet recruiting 2Withdrawn 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Breast 1

Conditions

Breast Neoplasms 28Neoplasms 26Prostatic Neoplasms 22Colorectal Neoplasms 17Head and Neck Neoplasms 14Pancreatic Neoplasms 11Lung Neoplasms 10Brain Neoplasms 10Neoplasm Metastasis 9Carcinoma, Renal Cell 9Squamous Cell Carcinoma of Head and Neck 8Melanoma 8Carcinoma, Non-Small-Cell Lung 8Triple Negative Breast Neoplasms 7Recurrence 7Precursor Cell Lymphoblastic Leukemia-Lymphoma 7Multiple Myeloma 7Lymphoma 7Glioblastoma 7Ovarian Neoplasms 6Lymphoma, Follicular 6Uterine Cervical Neoplasms 5Urinary Bladder Neoplasms 5Lymphoma, B-Cell 5Leukemia, Myeloid, Acute 5Leukemia 5Kidney Neoplasms 5Hematologic Neoplasms 5Sarcoma 4Liver Neoplasms 4

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Withdrawn × Locally Advanced Breast Cancer (LABC) × 1 year × Clear all
NCT07150767 2025-12-02

A Clinical Study to Explore the Safety, Tolerability, and Efficacy of Recombinant Human nsIL12 Oncolytic Adenovirus Injection (BioTTT001) Combined With Neoadjuvant Treatment for Locally Advanced Breast Cancer

Beijing Bio-Targeting Therapeutics Technology Co., Ltd

Phase 1 Withdrawn
Breast

Locally Advanced Breast Cancer (LABC)

Data powered by HemOnc (CC BY 4.0) Colophon âš¡